Immuneering Corporation
IMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.93 | 0.44 | 0.03 | -0.05 |
| FCF Yield | -4.32% | -7.79% | -26.09% | -21.26% |
| EV / EBITDA | -3.63 | -6.74 | -1.44 | -2.03 |
| Quality | ||||
| ROIC | -6.63% | -44.81% | -33.72% | -40.74% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.65 | 0.94 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -26.84% | 32.94% | 2.96% | -7.74% |
| Safety | ||||
| Net Debt / EBITDA | 15.03 | 1.52 | 2.06 | 1.79 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,671.63 | 0.00 | 0.00 | -1,009.29 |